ReviewExperimental & molecular medicine2026
Cell plasticity in cancer and therapy resistance.
Review in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cancer cell plasticity, the ability of tumor cells to switch between distinct cellular states, has emerged as a key mechanism driving tumor progression, metastasis and therapy resistance. Cancer cells exploit diverse plasticity mechanisms, including dedifferentiation, transdifferentiation, epithelial-mesenchymal transition and stem cell-like reprogramming, to adapt to changes in their microenvironment or therapeutic pressures. These transitions are orchestrated by signaling pathways, epigenetic modifications and microenvironmental cues. Notably, plasticity encompasses reversible transitions among intermediate states that enhance metastatic potential and contribute to therapeutic failure. Tumor cells can enter drug-tolerant reversible states, enabling survival during treatment and leading to relapse. Recent advances in single-cell and spatial transcriptomics, along with conceptual frameworks such as the Waddington landscape, have provided new insights into the dynamic regulation of tumor cell-state transitions at high resolution. In this Review, we discuss the molecular and cellular mechanisms governing cancer cell plasticity, its impact on metastasis and therapy resistance, and recent technological advances that illuminate dynamic tumor cell-state transitions.
Identifiers
42844350What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.